Avadel Pharmaceuticals (AVDL)
(Delayed Data from NSDQ)
$16.20 USD
-0.03 (-0.18%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $16.20 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
F Value A Growth F Momentum D VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
AVDL 16.20 -0.03(-0.18%)
Will AVDL be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for AVDL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AVDL
Is Actinium Pharmaceuticals (ATNM) Stock Outpacing Its Medical Peers This Year?
HUM Expands Musculoskeletal Care Access With New Value-Based Tie-Ups
AVDL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Does Avadel (AVDL) Have the Potential to Rally 27.95% as Wall Street Analysts Expect?
Acadia & ECU Health Expand Behavioral Care Access in North Carolina
Corcept Shares Rise 39.6% in YTD: How Should You Play the Stock?
Other News for AVDL
Doji - Bearish? appears for AVDL after 0.18% move
Stochastic Reached Overbought appears for AVDL after 3.64% move
Craig-Hallum Sticks to Their Buy Rating for Avadel Pharmaceuticals (AVDL)
Is AVDL preparing for a move? Bollinger Band Squeeze shows up after gaining 1.62%
Wells Fargo Reaffirms Their Hold Rating on Avadel Pharmaceuticals (AVDL)